- Home
- CNC vs IQV Comparison
CNC vs IQV Comparison
Compare CNC & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNC
- IQV
- Stock Information
- Founded
- CNC 1984
- IQV 1982
- Country
- CNC United States
- IQV United States
- Employees
- CNC N/A
- IQV N/A
- Industry
- CNC Medical Specialities
- IQV Biotechnology: Commercial Physical & Biological Resarch
- Sector
- CNC Health Care
- IQV Health Care
- Exchange
- CNC Nasdaq
- IQV Nasdaq
- Market Cap
- CNC 28.1B
- IQV 25.6B
- IPO Year
- CNC 2001
- IQV 2013
- Fundamental
- Price
- CNC $54.40
- IQV $154.78
- Analyst Decision
- CNC Buy
- IQV Buy
- Analyst Count
- CNC 16
- IQV 20
- Target Price
- CNC $77.87
- IQV $226.80
- AVG Volume (30 Days)
- CNC 4.2M
- IQV 2.3M
- Earning Date
- CNC 07-25-2025
- IQV 07-21-2025
- Dividend Yield
- CNC N/A
- IQV N/A
- EPS Growth
- CNC 33.19
- IQV 0.26
- EPS
- CNC 6.72
- IQV 7.35
- Revenue
- CNC $153,266,000,000.00
- IQV $15,497,000,000.00
- Revenue This Year
- CNC $23.62
- IQV $5.37
- Revenue Next Year
- CNC $0.59
- IQV $5.19
- P/E Ratio
- CNC $8.11
- IQV $21.12
- Revenue Growth
- CNC 7.22
- IQV 2.84
- 52 Week Low
- CNC $53.99
- IQV $134.65
- 52 Week High
- CNC $80.59
- IQV $252.88
- Technical
- Relative Strength Index (RSI)
- CNC 37.01
- IQV 55.12
- Support Level
- CNC $54.16
- IQV $153.23
- Resistance Level
- CNC $55.75
- IQV $159.85
- Average True Range (ATR)
- CNC 1.10
- IQV 4.39
- MACD
- CNC 0.06
- IQV 0.96
- Stochastic Oscillator
- CNC 19.43
- IQV 67.09
About CNC Centene Corporation
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
About IQV IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.